Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
CSE: CMND
FWB: CWY
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
23
November
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
Read More
17
November
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
Read More
11
October
Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
Read More
22
September
Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Read More
24
August
Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
Read More
21
June
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
Read More
15
June
Clearmind Medicine Appoints New Chief Financial Officer
Read More
7
June
Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
Read More
2
June
Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
Read More
1
June
Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India
Read More
26
May
Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder
Read More
24
May
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
Read More
19
May
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
Read More
13
May
Clearmind Announces Pre-IND Meeting Date with FDA
Read More
10
May
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination...
Read More
Next
